Posted by Michael Wonder on 14 Nov 2017
Cyltezo, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases
13 November 2017 - Approval follows recent positive CHMP opinion and FDA approval of Cyltezo.
Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation for Cyltezo, a biosimilar to Humira for the treatment of multiple chronic inflammatory diseases in adults and children.
